Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea

Digestive Diseases and Sciences

Volumn 57, Issue 5, 2012, Pages 1222-1226

  Wong, Banny S ^a   Camilleri, Michael ^a   Odunsi Shiyanbade, Suwebatu ^a   Busciglio, Irene ^a   Burton, Duane ^a   Carlson, Paula J ^a   McKinzie, Sanna ^a   Zinsmeister, Alan R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bile acid; FGFR4; Klotho

Indexed keywords

COLESEVELAM; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KLOTHO BETA PROTEIN; KLOTHO PROTEIN; PLACEBO; UNCLASSIFIED DRUG; ALLYLAMINE; BETA KLOTHO PROTEIN, HUMAN; BETA-KLOTHO PROTEIN, HUMAN; BILE ACID; DRUG DERIVATIVE; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED SCINTIGRAPHY; CONTROLLED STUDY; DIARRHEA; FEMALE; GASTROINTESTINAL TRANSIT; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BIOSYNTHESIS; BIOTRANSFORMATION; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEEDBACK SYSTEM; GENETICS; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BIOTRANSFORMATION; COLON; DIARRHEA; FEEDBACK, PHYSIOLOGICAL; FEMALE; FIBROBLAST GROWTH FACTORS; GASTROINTESTINAL TRANSIT; HUMANS; IRRITABLE BOWEL SYNDROME; MEMBRANE PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4;

EID: 84863619771     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2035-5     Document Type: Article

References (16)

1. Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol. 2009;7:1151-1154.
2. Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7:1189-1194.
3. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30:707-717.
4. Nyhlin H, Merrick MV, Eastwood MA, Brydon WG. Evaluation of ileal function using 23-selena-25-homotaurocholate, a-gammalabeled conjugated bile acid. Initial clinical assessment. Gastroenterology. 1983;84:63-68.
5. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8:159-165.
6. Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol. 1996;8: 117-123.
7. Wong BS, Camilleri M, Carlson PJ, et al. A klothob variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology. 2011;140:1934-1942.
8. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139:1549-1558.
9. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther. 2010;87:748-753.
10. Deiteren A, Camilleri M, Bharucha AE, et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil. 2010;22:415-423.
11. Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;92: 2671-2676.
12. Camilleri M, Nadeau A, Tremaine WJ, et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil. 2009;21:734-e43.
13. Spiller R, Camilleri M, Longstreth GF. Perspective: do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? The con argument. Clin Gastroenterol Hepatol. 2010;8:125-136.
14. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet. 2001;358:1504-1508.
15. El-Salhy M, Lomholt-Beck B, Gundersen D. The prevalence of celiac disease in patients with irritable bowel syndrome. Mol Med Rep. 2011;4:403-405.
16. Korkut E, Bektas M, Oztas E, Kurt M, Cetinkaya H, Ozden A. The prevalence of celiac disease in patients fulfilling Rome III criteria for irritable bowel syndrome. Eur J Intern Med. 2010;21:389-392.